Drug: Amjevita (adalimumab-atto)

Manufacturer: Amgen

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication:

• • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
  • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
  • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
  • reducing signs and symptoms in adult patients with active ankylosing spondylitis
  • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab
  • inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine
  • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

Disease: ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Therapeutic Area: Gastroenterology, Rheumatology, Dermatology, Immunology

Enrollment Form Link: www.amgensupportplus.com/patient/amjevita

Phone Number: 1-888-826-5384

Fax Number: 1-833-626-5384

Product Website: amjevita.com